What is Pivmecillinam?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Definition and Mechanism of Pivmecillinam

  • Pivmecillinam is the pro-drug of mecillinam, a beta-lactam antibiotic with a novel site of action and high activity against Gram-negative organisms such as Escherichia coli and other Enterobacteriaceae 1.
  • It has a specific mechanism of action, making it effective against certain bacteria, including those that cause urinary tract infections 2.

Clinical Use and Efficacy

  • Pivmecillinam has been widely used for the treatment of acute lower urinary tract infections (UTI), primarily in the Nordic countries, with a high success rate and low resistance levels 1, 3.
  • Clinical studies have shown that pivmecillinam is effective for the treatment of acute cystitis, with short-term treatment resulting in clinical and bacteriological cure rates similar to those obtained with other UTI agents 1, 2, 3.
  • It has also been used to treat other infections, including those caused by Staphylococcus saprophyticus, and has been found to be effective and well-tolerated in pregnant women 3.

Safety and Tolerability

  • Pivmecillinam has a benign safety and tolerability profile, with a low frequency of adverse effects such as diarrhea and Candida vaginitis 1, 4.
  • Studies have shown that pivmecillinam has a minor impact on the normal oropharyngeal, intestinal, and skin microflora, which contributes to its favorable safety profile 1.
  • A systematic review of over 40 years of clinical experience with pivmecillinam found that it has a low risk of adverse effects and is well-tolerated 4.

Resistance and Comparison to Other Antibiotics

  • Pivmecillinam has a low level of resistance among E. coli isolates, making it a suitable first-line agent for empirical treatment of acute cystitis 1, 2.
  • Comparative studies have shown that pivmecillinam is equivalent to other antimicrobial agents in terms of clinical and bacteriological outcomes, and may be a better option than other antibiotics due to its low resistance levels and favorable safety profile 1, 2, 3.

References

Research

Pivmecillinam--therapy of choice for lower urinary tract infection.

International journal of antimicrobial agents, 2003

Research

Pivmecillinam for the treatment of acute uncomplicated urinary infection.

International journal of clinical practice, 1999

Research

Pivmecillinam in the treatment of urinary tract infections.

The Journal of antimicrobial chemotherapy, 2000

Research

Safety and Tolerability of Pivmecillinam During More Than Four Decades of Clinical Experience: A Systematic Review.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.